STOCK TITAN

Twist Bioscience - TWST STOCK NEWS

Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.

Overview of Twist Bioscience Corp

Twist Bioscience Corp is a pioneering synthetic biology company that has redefined the process of DNA synthesis using a proprietary semiconductor-based manufacturing platform. The company leverages innovative technology to produce high-quality synthetic DNA rapidly and cost-effectively. This breakthrough approach, characterized by synthesizing DNA on silicon rather than traditional plastic wells, positions Twist Bioscience as a disruptive force in the biotechnological landscape, driving advances in applications from biomedical research to industrial biotechnology.

Proprietary Technology and Manufacturing Process

At the heart of Twist Bioscience's operations is a state-of-the-art synthetic DNA manufacturing process. By employing a 10,000-well silicon platform, the company sidesteps the limitations inherent in conventional methods. The integration of semiconductor technology not only minimizes production inefficiencies but also ensures high throughput, which is crucial for applications requiring rapid gene synthesis and customization. This technical ingenuity underpins the company's ability to deliver:

  • High-quality oligonucleotides
  • Custom genes and genetic pathways
  • Complex chassis and complete genomes

Business Model and Revenue Generation

Twist Bioscience's business model is built on the dual pillars of technology licensing and direct sales. The company generates revenue by offering its synthetic DNA products to a wide range of customers including academic research institutions, biotechnology firms, and industrial manufacturers. Its cost-effective, rapid production capabilities allow clients to accelerate their research and development efforts, thereby reducing time-to-market for various applications. This operational efficiency is not only beneficial to its clients but also reinforces the company’s reputation for reliability and scalability in the synthetic biology market.

Market Position and Competitive Landscape

Operating in a highly specialized niche, Twist Bioscience has carved a unique position in the competitive synthetic biology ecosystem. The company differentiates itself through its disruptive manufacturing process and its capacity to produce synthetic biology tools at scale. In a market where reliability, speed, and cost-efficiency are paramount, Twist Bioscience’s strategic focus on overcoming production inefficiencies positions it as a significant player. Its technology challenges traditional paradigms and compels competitors to reconsider conventional manufacturing methods, thereby affirming its role as an innovator rather than a mere participant in the industry.

Applications and Industry Impact

The technology developed by Twist Bioscience has far-reaching implications across numerous sectors. In the field of biomedical research and personalized medicine, its rapid DNA synthesis paves the way for new diagnostics, targeted therapies, and advanced research into genetic disorders. Beyond healthcare, the company’s synthetic biology tools enable innovations in sustainable chemical production and improved agricultural practices, broadening the scope of applications into:

  • Biopharmaceutical research: Accelerating drug discovery and genetic screening.
  • Industrial biotechnology: Optimizing production processes for chemicals and materials.
  • Environmental monitoring: Developing in vivo diagnostics and biodetection solutions.

This multi-sector applicability underscores the versatility and transformative potential of Twist Bioscience's platform. By industrializing the engineering of biology, the company not only enhances research capabilities but also contributes significantly to sectors that rely on synthetic DNA for innovation and efficiency.

Operational Excellence and Research Ecosystem

Central to the success of Twist Bioscience is its commitment to operational excellence and continuous innovation. The company collaborates with a diverse ecosystem of researchers, academic institutions, and industrial partners, fostering an environment where technological breakthroughs are routinely translated into practical solutions. This collaborative approach ensures that every advancement in its manufacturing process is both rigorously validated and immediately deployable across a spectrum of research and industrial applications.

Scientific and Technical Expertise

Twist Bioscience is driven by a deep reservoir of scientific and technical expertise. The company’s team, comprised of leading experts in synthetic biology, semiconductor physics, and bioengineering, is instrumental in refining its technology and pushing the boundaries of what is possible in DNA synthesis. This expertise not only strengthens the company’s competitive position but also instills confidence in its ability to deliver reliable, high-quality synthetic biology products that meet the evolving needs of modern research and industry.

Integration into the Broader Biotechnology Landscape

The innovations from Twist Bioscience resonate well within the broader biotechnology and life sciences arenas. Its approach to DNA synthesis using semiconductor-based technology is widely recognized for its potential to revolutionize how genetic materials are produced and utilized. This integration of advanced material science with biotechnology exemplifies the cross-disciplinary innovation that is becoming increasingly important. Researchers and industrial partners alike appreciate the capacity for simultaneous high throughput and high precision, enabling a smoother transition from conceptual breakthroughs to tangible products.

Commitment to Quality and Reliability

Quality control and reliability are fundamental to Twist Bioscience’s operations. The company’s advanced manufacturing process ensures consistency and precision in synthetic DNA production. By employing robust quality assurance protocols throughout its production cycle, Twist Bioscience provides products that research institutions and industry players can depend upon for critical applications. This unwavering focus on quality not only supports current operational needs but also cements the company’s reputation as a trustworthy provider of synthetic biology tools.

Position within the Competitive Landscape

While the synthetic biology sector is competitive, Twist Bioscience’s distinctive approach allows it to maintain a unique market niche. Its semiconductor-based platform, coupled with the extensive scale and precision of production, sets it apart from more traditionally operated competitors. The company’s strategy of addressing the inherent inefficiencies of standard DNA synthesis methods resonates with clients looking for innovative solutions. This unique value proposition has enabled Twist Bioscience to develop a strong foothold in its primary markets, particularly in regions known for high research and development activity.

Conclusion

In summary, Twist Bioscience Corp represents a significant advancement in synthetic biology. Through its disruptive semiconductor-based synthetic DNA platform, the company not only accelerates research and industrial processes but also redefines the standards of cost efficiency and production quality. Its integrated approach, encompassing innovative technology, rigorous quality control, a collaborative research ecosystem, and a clear focus on operational excellence, makes it a compelling case study in modern biotechnology innovations. The breadth of its applications and its ability to deliver high-quality synthetic DNA at scale underscore its impact on the biotechnology industry and its sustained position in the competitive landscape.

Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) reported a record revenue of $75.3M in the second quarter of fiscal 2024, showing a 25% increase over the same period in fiscal 2023. Orders also grew by 45% to $93.2M. The company increased its revenue guidance for fiscal 2024 to a range of $300M to $304M and its gross margin guidance to 41.5% to 42.0%. Twist Bioscience continues to focus on profitability and aims to improve gross margin to over 50% by the end of fiscal 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.74%
Tags
-
Rhea-AI Summary
Twist Bioscience (NASDAQ: TWST) will report its fiscal 2024 second-quarter financial results on May 2, 2024, after the market closes. The company will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. The press release and webcast will be accessible on the company's website. Telephone participants can register on the Investor Relations website to receive the dial-in number and unique PIN for access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences earnings
-
Rhea-AI Summary
Twist Bioscience (NASDAQ: TWST) launches a new Human Pangenome Spike-in for the Twist Exome 2.0 panel to enhance genetic variation detection during whole exome sequencing. The tool aims to provide a more comprehensive view of human genetic diversity, leveraging the Human Pangenome Reference Consortium's diverse genomic data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announces CE-marked Precision Dx Products compliant with EU IVDR regulations, including Twist Precision Prep and Enrichment Dx Kit, Twist Precision Exome Dx Panel, and Twist Precision Exome Dx Kit. The products aim to facilitate panel sequencing within clinical settings, meeting high quality standards. Twist collaborates with Platomics to streamline documentation generation and regulatory compliance. CEO Emily M. Leproust highlights the significance of IVDR certification for diagnostic tests and the company's commitment to supporting European customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (TWST) executives will participate in fireside chats at upcoming investor conferences, including TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference. The chats will be webcast live and available for replay for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
conferences
-
Rhea-AI Summary
Twist Bioscience Corporation (TWST) announced the grant of 122,400 restricted stock units (RSUs) to 36 recently hired individuals as an employment inducement. The RSUs vest over a 48-month period, with 25% vesting on the one year anniversary of the start date of the employee, and 1/16 of the RSUs vesting on each quarterly anniversary thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) and Element Biosciences, Inc. announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System. The collaboration aims to offer customers an economical and streamlined approach to next generation sequencing. The Exome 2.0 panel and high performing library preparation and target enrichment reagents are designed to provide best-in-class sequencing, detect rare and inherited diseases, and germline cancers. The purpose-built solution for Element’s AVITI chemistry will reduce per sample sequencing requirements, potentially saving downstream sequencing costs. The companies have ambitious product roadmaps for 2024 to make sequencing even easier for labs to produce the highest quality data at a low cost.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (TWST) has launched the cfDNA Library Preparation Kit to enable liquid biopsy research, addressing challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input. The kit can detect rare allele variants due to its high conversion rate and protocols minimize sample handling for a streamlined workflow and results delivered within two hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announced the early access of the Twist Flex Prep Ultra High-Throughput (UHT) Kit, a novel technology that aims to enable unparalleled throughput at a fraction of the cost of existing on-market solutions. The kit utilizes novel chemistry that accepts and self-normalizes a wide range of sample input amounts through a new proprietary Normalization By Ligation (NBL) technology, crucial for researchers in AgBio who sequence thousands of samples of varying inputs. The technology is positioned to drive NGS adoption in agricultural genomics, enabling streamlined, scalable, and cost-effective workflows for high-throughput applications in breeding, trait selection, and other research areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) reported record revenue of $71.5M in 1QFY24, a 32% increase over 1QFY23. Orders increased to $77.5M, a 19% increase over 1QFY23. The company raised its FY 2024 revenue guidance to $288M to $293M and increased FY 2024 gross margin guidance to 40% to 41%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.01%
Tags

FAQ

What is the current stock price of Twist Bioscience (TWST)?

The current stock price of Twist Bioscience (TWST) is $38.94 as of April 1, 2025.

What is the market cap of Twist Bioscience (TWST)?

The market cap of Twist Bioscience (TWST) is approximately 2.3B.

What is Twist Bioscience's core business?

Twist Bioscience focuses on synthetic biology by utilizing a proprietary semiconductor-based platform to synthesize high-quality DNA. Its core business involves manufacturing synthetic DNA for research, industrial biotechnology, and biomedical applications.

How does Twist Bioscience's technology differ from traditional methods?

The company synthesizes DNA on silicon rather than on conventional plastic plates, enabling cost-effective, rapid, and high-throughput production while overcoming common inefficiencies in traditional synthesis methods.

Which industries benefit from Twist Bioscience's products?

Industries ranging from biomedical research and personalized medicine to industrial biotechnology and sustainable chemical production benefit from their high-quality synthetic DNA products.

What are the primary products provided by Twist Bioscience?

Twist Bioscience produces a range of synthetic biology tools including oligonucleotides, genes, genetic pathways, chassis, and complete genomes, all synthesized using their advanced silicon-based platform.

How does the company's business model support its operations?

The company generates revenue through direct sales and technology licensing, offering high-quality synthetic DNA products that enhance research capabilities and industrial production efficiency.

What competitive advantages does Twist Bioscience hold in the synthetic biology market?

Their proprietary technology, which leverages semiconductor manufacturing techniques, allows them to produce DNA faster and more cost-effectively than traditional methods, positioning them uniquely in the competitive landscape.

Who are the primary customers of Twist Bioscience?

Twist Bioscience serves a diverse customer base including academic research institutions, biotechnology companies, and industrial manufacturers requiring reliable synthetic DNA production for various applications.

How does Twist Bioscience ensure the quality of its synthetic DNA products?

By integrating rigorous quality control protocols within its manufacturing process, the company ensures consistent and precise production, making its products dependable for critical research and industrial applications.
Twist Bioscience

Nasdaq:TWST

TWST Rankings

TWST Stock Data

2.34B
58.41M
2.16%
112.29%
15.59%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO